Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
Authors
Keywords
-
Journal
PLoS One
Volume 7, Issue 6, Pages e38364
Publisher
Public Library of Science (PLoS)
Online
2012-06-16
DOI
10.1371/journal.pone.0038364
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma
- (2011) Vincenzo De Giorgi et al. ARCHIVES OF INTERNAL MEDICINE
- Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer
- (2011) J. C. Kim et al. CLINICAL CANCER RESEARCH
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Beta Blockers and Breast Cancer Mortality: A Population- Based Study
- (2011) Thomas I. Barron et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
- (2011) Amal Melhem-Bertrandt et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Trial of Bevacizumab and High-dose Interferon Alpha 2B in Metastatic Melanoma
- (2011) Valerie P. Grignol et al. JOURNAL OF IMMUNOTHERAPY
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors
- (2010) M. Del Vecchio et al. CLINICAL CANCER RESEARCH
- MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC
- (2010) Christian Busch et al. EUROPEAN JOURNAL OF CANCER
- Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism
- (2010) Soon Young Park et al. INTERNATIONAL JOURNAL OF CANCER
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma
- (2010) Pia P. Vihinen et al. MELANOMA RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting angiogenesis in melanoma: prospects for the future
- (2010) P.G. Corrie et al. Therapeutic Advances in Medical Oncology
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
- Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma
- (2009) Lars A. Akslen et al. MELANOMA RESEARCH
- Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis
- (2008) Vera J. Suman et al. CANCER INVESTIGATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started